Heart Failure Clinical Trials

Find Heart Failure Clinical Trials Near You

Assessing the Ability to Improve the Diagnosis of Heart Failure With Preserved Ejection Fraction Using Advanced Imaging Techniques

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Diagnostic test
Study Type: Observational
SUMMARY

Heart failure with preserved ejection fraction (HFpEF) causes symptoms of breathlessness and leg swelling. It is associated with significant number of hospital admissions and could lead to the patient's death. In HFpEF, the pumping function of the heart is normal but the heart is too stiff to fill properly. The first line investigation is an ultrasound of the heart (echocardiography). A number of parameters are assessed that indicate stiffness within the heart or raised pressures within the heart. However, most of these parameters lack sensitivity which can make HFpEF difficult to diagnose. The best test is to invasively measure the pressures in the heart at rest and with exercise in a procedure called heart catheterisation. However, this is invasive and not readily available. As a result, HFpEF is significantly under diagnosed meaning many patients do not get access to disease specific treatment that may improve symptoms and quality of life. There are a number of new imaging techniques that may help us to better identify HFpEF . However, it is not currently known how to best apply them in clinical practice. In this study, the investigators will recruit patients presenting to the HF clinic at Sheffield Teaching Hospitals who have symptoms of HFpEF but whose diagnosis remains unclear after initial assessment. The impact of their symptoms will be assessed with the use of a quality of life (QoL) questionnaires and a six-minute walk test (6MWT). They will undergo advanced imaging with a specialist echocardiogram and a cardiac MRI scan. If they are found to have features of HFpEF, they will be started on disease specific treatment. All patients will be followed up after six months to see if they have any symptomatic or functional improvement. They will also undergo repeat imaging to see if there has been any change in the imaging parameters.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female \> 18yrs of age.

• Symptoms of dysponea on exertion.

• NTproBNP \>400 ng/L in sinus rhythm (SR).

• Baseline TTE demonstrating a dilated LA (LA\>34 ml/m2), but that otherwise does not meet the current criteria for the diagnosis of HFpEF or HFrEF (preserved LV systolic function, Normal E/e', no evidence of LVH, Estimated PAP \< 35mmhg).

Locations
Other Locations
United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
RECRUITING
Sheffield
University of Sheffield
NOT_YET_RECRUITING
Sheffield
Time Frame
Start Date: 2025-08-05
Estimated Completion Date: 2027-09-30
Participants
Target number of participants: 40
Treatments
No therapy intervention
cMRI \& TTE, no further intervention
Therapy intervention
cMRI \& TTE, SGLT-2 inhibitor therapy
Sponsors
Leads: Sheffield Teaching Hospitals NHS Foundation Trust

This content was sourced from clinicaltrials.gov